Jaguar Health (JAGX) announced that four dogs have now been enrolled in Jaguar’s ongoing field study of Canalevia-CA1, the company’s U.S. Food and Drug Administration conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea in dogs, and enrollment is continuing. Six veterinary oncology clinics have signed on to take part in this study, and Jaguar is in discussions with other veterinary oncology clinics regarding possible participation. Jaguar plans to submit a dossier to the European Medicines Agency to outline the results of the updated analysis of the company’s completed study of Canalevia in dogs with general diarrhea. If acceptable to the EMA, the company will then submit a Marketing Authorization Application for Canalevia for general diarrhea in dogs. If the application is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health announces coca access, benefit sharing agreement authorization
- Jaguar Animal Health Issues Series M Preferred Stock
- Jaguar Health announces initial proof-of-concept results on crofelemer
- Jaguar Health board authorizes crypto as treasury reserve asset
- Jaguar Health to pursue approval of Canalevia in EU for general diarrhea in dogs